Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Revenue: 2022-2025

Historic Revenue for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $1.1 million.

  • InMed Pharmaceuticals' Revenue fell 11.43% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year decrease of 3.27%. This contributed to the annual value of $4.9 million for FY2025, which is 7.50% up from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Revenue is $1.1 million, which was down 14.15% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Revenue peaked at $2.3 million during Q2 2023, and registered a low of $309,585 during Q1 2022.
  • In the last 3 years, InMed Pharmaceuticals' Revenue had a median value of $1.2 million in 2023 and averaged $1.3 million.
  • Its Revenue has fluctuated over the past 5 years, first spiked by 348.96% in 2023, then tumbled by 44.48% in 2024.
  • Over the past 4 years, InMed Pharmaceuticals' Revenue (Quarterly) stood at $469,783 in 2022, then skyrocketed by 163.99% to $1.2 million in 2023, then declined by 10.36% to $1.1 million in 2024, then dropped by 11.43% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.3 million for Q2 2025, and $1.3 million during Q1 2025.